公开(公告)号：US20210015941A1

公开(公告)日：2021-01-21

申请号：US16933845

申请日：2020-07-20

Applicant: ImmuneSensor Therapeutics, Inc. ,  The Board of Regents of the University of Texas System

Inventor： Zhijian CHEN ,  Heping SHI ,  Qi WEI ,  Chuo CHEN ,  Lijun SUN ,  Jian QIU ,  Youtong WU

IPC: A61K47/68 ,  A61P35/00

Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.

公开(公告)号：US10889637B2

公开(公告)日：2021-01-12

申请号：US16078990

申请日：2017-02-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Jean X. Jiang ,  Zhiqiang An ,  Ningyan Zhang ,  Wei Xiong ,  Manuel A. Riquelme ,  Sumin Gu ,  Naomi Ledene Sayre

IPC: C07K16/18 ,  A61P25/28 ,  A61P19/10 ,  A61K39/395 ,  A61P35/00

Abstract: Antibodies that bind to connexin 43 hemichannels and inhibit, or activate, channel opening are provided. In certain aspects, methods for detecting or treating cancers with antibodies that activate Cx43 channel opening are also provided. Likewise, methods for treating inflammatory diseases (e.g., osteoarthritis) and neurological injuries (e.g., spinal cord injury) with antibodies that inhibit Cx43 channel opening are provided.

公开(公告)号：US20200333350A1

公开(公告)日：2020-10-22

申请号：US16814898

申请日：2020-03-10

Applicant: The Board of Regents of the University of Texas System

Inventor： Jinming GAO ,  David BOOTHMAN ,  Kejin ZHOU ,  Xiaonan HUANG ,  Yiguang WANG

IPC: G01N33/58

Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R′ is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.

公开(公告)号：US20200330442A1

公开(公告)日：2020-10-22

申请号：US16915506

申请日：2020-06-29

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zelton Dave SHARP ,  Randy STRONG ,  Paul HASTY ,  Carolina LIVI ,  Arlan RICHARDSON

IPC: A61K31/436 ,  A61K31/415 ,  A61K31/192 ,  A61K9/51 ,  A61K45/06

Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).

公开(公告)号：US20200328877A1

公开(公告)日：2020-10-15

申请号：US16845556

申请日：2020-04-10

Applicant: The Board of Regents of the University of Texas System

Inventor： Alekhya MUTHINENI ,  Eugene JOHN

IPC: H04L9/06 ,  G06F1/26

Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.

公开(公告)号：US20200323879A1

公开(公告)日：2020-10-15

申请号：US16813017

申请日：2020-03-09

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Thomas J. SLAGA ,  Jacob JUNCO ,  Huiyun LIANG ,  Sara REYNA

IPC: A61K31/56 ,  A61K31/19 ,  A61K31/05 ,  A61K9/00

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

公开(公告)号：US10799466B2

公开(公告)日：2020-10-13

申请号：US16434541

申请日：2019-06-07

Applicant: The Board of Regents of the University of Texas System

Inventor： Phillip C. Phan ,  Allen W. Burton

IPC: A61K9/19 ,  A61K9/08 ,  A61K31/07 ,  A61K31/02 ,  A61K9/00

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

公开(公告)号：US20200306313A1

公开(公告)日：2020-10-01

申请号：US16900178

申请日：2020-06-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Senlin LI ,  Robert A. CLARK ,  Cang CHEN

IPC: A61K35/28 ,  A61M1/38 ,  C12N5/0789 ,  A61K31/395 ,  A61K38/19 ,  A61M1/34

Abstract: Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.

公开(公告)号：US20200260698A1

公开(公告)日：2020-08-20

申请号：US16639828

申请日：2018-08-17

Applicant: The Board of Regents of the University of Texas System

Inventor： Viktoriia KYRYCHENKO ,  Eric N. OLSON ,  Rhonda BASSEL-DUBY

IPC: A01K67/027 ,  C12N15/10 ,  C12N15/113 ,  A61P21/00

Abstract: CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene and absence or deficiency of dystrophin protein in striated muscle. Provided herein are compositions and methods for treating DMD caused by mutations in the dystrophin Actin Binding Domain 1 (ABD-1). The compositions and method described herein can be used to remove mutant sequences in dystrophin ABD-1 to generate a corrected DMD protein that, while lacking one or more exons (e.g., exons 3-9), retains important functional properties.

公开(公告)号：US20200246278A1

公开(公告)日：2020-08-06

申请号：US16636478

申请日：2018-08-06

Applicant: University of Houston System ,  Board Of Regents Of The University Of Texas System

Inventor： Diana S-L Chow ,  Tanay S. Samant ,  Shi-Ming Tu

IPC: A61K31/05 ,  A61K9/16 ,  A61K9/00 ,  A61P35/00

Abstract: Embodiments of the present disclosure pertain to formulations for cancer treatment that include a particle loaded with diethylstilbestrol (DES) and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may also be loaded into the particle. The formulations may also include a stabilizer that is also loaded into the particle. The particles may be dispersed in an aqueous solution to form a nanosuspension that is adapted for subcutaneous administration and sustained release of DES. Additional embodiments pertain to methods of treating cancer in a subject by administering to the subject a formulation of the present disclosure. The subject may be a human suffering from prostate cancer. The administration of the formulations to the subject may bypass or minimize first pass metabolism. The administration may also minimize hepatic exposure of DES. Additional embodiments pertain to methods of making the formulations of the present disclosure by loading a particle with DES.